West Pharmaceutical stock: What you should know now before buying
This report examines West Pharmaceutical Services, a key supplier in the medtech space for injectable drug packaging and delivery systems. It covers the company's business model, growth drivers, competitive position, and risks for investors. The article highlights how West Pharmaceutical benefits from the expanding injectable drug market and its strong moat through proprietary technology and established partnerships.
Eli Lilly (LLY) CEO Says Company Ready to Scale Production of Weight-Loss Pill
Eli Lilly's CEO, Dave Ricks, announced the company is prepared to massively scale production and distribution of its newly approved weight-loss pill, Foundayo, to meet anticipated global demand. Following FDA approval, Eli Lilly expects regulatory approvals in over 40 countries this year. Foundayo is poised to be more appealing than injectable alternatives, and Wall Street analysts currently give LLY stock a consensus Strong Buy rating.
Bahl & Gaynor Income ETF BGIG Sees $1.5 Billion in Inflows
The Bahl & Gaynor Income Growth ETF (BGIG) recently saw an unprecedented $1.5 billion in inflows within a single week, dramatically increasing its assets under management. This substantial influx of capital highlights investor confidence in BGIG's strategy, which focuses on high-quality equity income derived from established companies like Johnson & Johnson and Microsoft, offering both growth and downside protection amid current market uncertainties. The fund's strong performance, including a 3.24% year-to-date NAV increase and a 2.05% SEC yield as of March 31, 2026, further validates its appeal as a lower-risk income approach.
Oppenheimer Urges Investors To buy McDonald’s Dip As Stock Falls 10%
Oppenheimer has reiterated an Outperform rating and a $355 price target for McDonald's (MCD) stock, seeing a buying opportunity after a nearly 10% dip from its February high. Key catalysts include the revamped McValue platform and a new McCafe beverage lineup. The investment bank's thesis highlights underappreciated unit growth, strong international sales, and improving margins for the fast-food giant.
Lexaria Applauds Eli Lilly's Foundayo Drug Approval
Lexaria Bioscience Corp. (Nasdaq: LEXX) recognizes the FDA approval of Eli Lilly's oral GLP-1 drug, Foundayo™, for obesity and weight-related conditions, highlighting the expanding market for oral weight-loss treatments. Lexaria's DehydraTECH™ technology aims to reduce the side effects commonly associated with these drugs, having already shown success in mitigating adverse events with other GLP-1 medications like semaglutide. The company plans further testing of DehydraTECH with other GLP-1 drugs including Foundayo™ to improve patient experience.
Sleep-disorder company Vivos gets $2.25M from repeat investor
Vivos Therapeutics (NASDAQ: VVOS) secured $2.25 million in a private placement from New Seneca affiliate V-Co 3, which includes the conversion of a prior $1.4 million bridge note. This brings Seneca's total investment in Vivos since 2024 to $13.4 million, demonstrating continued support for Vivos's medical affiliation model and goal of achieving breakeven cash flow by the end of 2026. Despite the capital injection, the market reacted negatively, with VVOS stock declining 9.15%, likely due to concerns over potential dilution from issued warrants.
AC Immune Secures Amended Tau Drug Collaboration with Lilly, Adds CHF 10 Million Upfront
AC Immune and Eli Lilly have amended their 2018 collaboration agreement for developing Tau aggregation inhibitor small molecules, including new lead Morphomer Tau candidates, targeting Alzheimer's and other neurodegenerative diseases. The revised deal provides AC Immune with a CHF 10 million upfront payment, a Phase 1 dosing milestone, and potential future milestones exceeding CHF 1.7 billion, along with low double-digit tiered royalties, strengthening its financial position and role in Tau-targeted drug development. Currently, TipRanks' AI Analyst Spark rates ACIU as Neutral due to weak financial performance despite low debt.
A third oral GLP-1 wins FDA approval, and Lexaria sees an opening
Lexaria Bioscience Corp. applauded the FDA approval of Eli Lilly's oral GLP-1 drug Foundayo for adult weight control, expanding the number of oral GLP-1 options to three. Lexaria sees this as an opportunity to integrate its DehydraTECH technology, which has shown promise in reducing the side effects commonly associated with GLP-1 drugs, into new formulations. Despite the positive market validation for oral GLP-1s, Lexaria's stock (LEXX) experienced an 8.44% decline following the news.
Ademi Firm Investigates Centessa Pharmaceuticals Buyout Price
The Ademi law firm is investigating whether Centessa Pharmaceuticals' board of directors is upholding its fiduciary duties to shareholders in the proposed $38 per share acquisition by Eli Lilly. The investigation focuses on whether the offer, which includes additional contingent value rights, provides a fair price for shareholders, especially given potential conflicts of interest and limitations on seeking competing bids. Shareholders are encouraged to contact Ademi LLP to learn more about the investigation.
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
Halozyme Therapeutics, Inc. has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals for its Hypercon™ technology. This microparticle technology aims to reduce drug injection volumes, enabling more convenient at-home administration. The agreement includes a $15 million upfront payment to Halozyme, with potential for future milestone payments and royalties on net sales of developed products.
AC Immune (NASDAQ: ACIU) amends Lilly Tau deal with CHF 10m upfront
AC Immune SA announced an amendment to its collaboration agreement with Eli Lilly and Company for the research and development of Tau aggregation inhibitor small molecules. Under the revised terms, AC Immune will receive an upfront payment of CHF 10 million and an additional milestone payment upon Phase 1 dosing. The company remains eligible for over CHF 1.7 billion in future milestones and tiered low double-digit royalties, and anticipates starting IND-enabling studies for new Tau Morphomer candidates imminently.
OpenAI, WHOOP gains lift SuRo Capital as Magnetar joins adviser plan
SuRo Capital announced a plan to transition to an externally managed structure through a joint venture with Magnetar, Neostellar Advisors LLC, aiming to enhance shareholder value and investment capabilities. The company also provided a preliminary Q1 2026 investment portfolio update, estimating its Net Asset Value (NAV) to be between $14.00 and $14.50 per share, largely due to strong performance in holdings such as OpenAI and WHOOP. This externalization, subject to stockholder approval, is expected to bring expense savings and preserve realized gains for stockholders.
Smart Insulin Management Devices Market is expected to Hit US$ 27.07 Billion by 2033 | Major Companies - Abbott, Medtronic, Tandem Diabetes Care, Inc., Eli Lilly and Company
The Smart Insulin Management Devices Market reached US$ 12.93 Billion in 2024 and is projected to grow to US$ 27.07 Billion by 2033, exhibiting an 8.6% CAGR during the forecast period. This growth is driven by advanced medical devices integrating insulin delivery with real-time monitoring and data analytics to optimize diabetes care. Key players include Abbott, Medtronic, and Eli Lilly, with significant industry developments in cloud-based AI analytics, bundled reimbursement programs, and closed-loop automated insulin delivery systems.
AC Immune stock rises after amending Lilly deal (ACIU:NASDAQ)
AC Immune (ACIU) stock rose after the Swiss biotech announced an amendment to its 2018 license and collaboration agreement with Eli Lilly (LLY). The deal focuses on developing Morphomer Tau, a new class of neurology therapies.
Press Release: AC Immune Announces Amendment to Morphomer (R) Tau License and Collaboration Agreement With Lilly
AC Immune has announced an amendment to its Morphomer® Tau License and Collaboration Agreement with Lilly. This amendment affects the financial terms of the agreement, including upcoming milestone payments and potential sales royalties related to Lilly's tau aggregate-specific antibody programs. The collaboration aims to accelerate the development of precision medicines for Alzheimer's and other neurodegenerative diseases.
Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema study
Sanofi's lunsekimig, a bispecific TSLP and IL-13 inhibitor, demonstrated success in two Phase 2 studies for respiratory diseases, significantly reducing asthma exacerbations and nasal polyps. However, the drug failed to meet its primary endpoint in a Phase 2b eczema trial for moderate-to-severe atopic dermatitis, despite showing improvements in secondary endpoints. These mixed results highlight the drug's potential for respiratory conditions but underscore Sanofi's ongoing challenge in finding a successor to its blockbuster eczema drug, Dupixent.
Aberdeen Group plc Sells 322,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR
Aberdeen Group plc significantly reduced its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 54.9%, selling 322,000 shares and now holding 264,869 shares. Despite this sell-off, institutional ownership remains high at 91.78%, with several other firms increasing their positions. Structure Therapeutics missed its latest EPS estimates but still carries a "Moderate Buy" consensus rating from analysts with an average price target of $110.00.
Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
Novo Nordisk's new GLP-1 pill, Wegovy, is attracting a significant number of new patients to obesity treatment, many of whom previously avoided injections due to fear of needles or high costs. While early demand has been explosive, driven by a lower entry price, the long-term effectiveness and demand for the pill will be tested as patients reach higher doses and face competition from rivals like Eli Lilly.
Viking Therapeutics, Inc. (VKTX) latest stock news and headlines
This article provides a compilation of recent news and headlines concerning Viking Therapeutics, Inc. (VKTX) stock, including its performance relative to the market and updates on its obesity drug trials. It features several headlines from financial news outlets like Zacks and Simply Wall St., discussing stock dips, analyst opinions, and enrollment milestones for VK2735. The article also provides key financial data for VKTX and other market indicators.
Mesoblast’s Ryoncil Achieves US$30.3 Million in Net Sales for March Quarter
Mesoblast Limited announced strong sales results for its product Ryoncil, with net sales reaching US$30.3 million for the quarter ending March 31, 2026. This performance contributed to nearly US$100 million in revenue since Ryoncil's launch, strengthening the company's balance sheet. Mesoblast will host an R&D Day on April 8, 2026, to discuss its growth strategy for Ryoncil and its pipeline, emphasizing the product's significance as the first FDA-approved mesenchymal stromal cell product.
Healthcare, Financials ETFs Get A Mega-Cap Reset With TRUF, TRUH
VanEck has launched two new TruSector ETFs, TRUF (Financials) and TRUH (Healthcare), designed to provide more precise and less diluted exposure to mega-cap leaders within their respective sectors. These ETFs aim to address the diversification constraints of traditional sector ETFs under RIC rules, allowing for meaningful allocations to dominant companies. Both funds feature a competitive expense ratio of 0.10% and maintain compliance while striving for cleaner sector representation and reduced tracking error.
A Look At Zai Lab (ZLAB) Valuation After New Amgen Oncology Collaboration News
Zai Lab (ZLAB) is gaining investor attention following a new oncology collaboration with Amgen. Despite a recent share price surge, the stock is trading significantly below analyst targets and intrinsic value estimates, suggesting it might be undervalued. Analysts project substantial revenue growth and improved profit margins for Zai Lab over the next three years.
Mckesson Corp Stock (MCK) Closed Down by 3.20% on Apr 6: Key Drivers Unveiled
McKesson Corp (MCK) stock closed down 3.20% on April 6, primarily due to B of A Securities lowering its price target and recent insider selling activity. Additionally, major institutional investors like UBS and T. Rowe Price reduced their holdings in the previous quarter. Despite these pressures, McKesson reported strong Q3 FY2026 results and raised full-year EPS guidance, indicating the decline was not due to operational performance.
Eli Lilly and Company (NYSE:LLY) Stock Price Down 1% on Analyst Downgrade
Eli Lilly and Company (NYSE:LLY) shares dropped 1% after Wall Street Zen downgraded the stock from "strong-buy" to "buy." Despite the intraday dip, analysts maintain a "Moderate Buy" consensus target of $1,222.22, citing catalysts like FDA approval for oral GLP-1 Foundayo, a Medicare/Medicaid access pact, a new production plant, and the planned Centessa acquisition. The company also reported strong Q4 earnings, beating expectations with an EPS of $7.54 and revenue of $19.29 billion, and set a positive FY2026 guidance.
Rocket Pharmaceuticals (NASDAQ: RCKT) seeks vote on director slate and option exchange
Rocket Pharmaceuticals (NASDAQ: RCKT) is holding its 2026 annual stockholder meeting on May 20, 2026, to vote on the election of seven directors, the ratification of EisnerAmper LLP as auditor, a non-binding advisory vote on executive pay, and the approval of a stock option exchange program. This virtual meeting will also address a 2025 strategic reorganization that reduced headcount by 30% and is expected to cut operating expenses by nearly 25%. The proposed stock option exchange program aims to enhance employee retention and motivation by allowing eligible employees to exchange "underwater" stock options for new options on a value-neutral basis, thereby reducing equity overhang.
Wegovy beats Foundayo in Novo Nordisk weight loss study
Novo Nordisk announced that its oral semaglutide, Wegovy, demonstrated superior weight loss compared to Eli Lilly's rival drug, Foundayo. A cross-trial comparison revealed that Wegovy achieved 3.2 percentage points more weight loss, while Foundayo experienced significantly higher dropout rates due to adverse side effects. This indicates a competitive edge for Novo Nordisk in the weight loss medication market.
Mixed options sentiment in Novo Nordisk with shares down 0.39%
Novo Nordisk (NVO) shares are down 0.39%, trading near $36.84, with mixed options sentiment. While overall options volume is relatively light, calls are leading puts, resulting in a put/call ratio of 0.62, which is lower than the typical 0.72. The implied volatility (IV30) has increased by 4.4 points to 47.96, suggesting a potential daily price movement of $1.11, and the put-call skew has flattened, indicating a modestly bullish outlook.
Assessing Stoke Therapeutics (STOK) Valuation After Strong 1 Year Shareholder Returns
Stoke Therapeutics (STOK), a clinical-stage biotech focusing on severe genetic diseases, has seen significant 1-year shareholder returns, prompting a valuation assessment. Despite recent short-term share price declines, the company is considered modestly undervalued at $32.74 against a narrative fair value of $34.25, according to analyst consensus. This valuation is based on expectations of future earnings growth and profit margins, though there is a range in analyst price targets, and the valuation could be sensitive to clinical trial outcomes like Phase 3 data for zorevunersen.
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion, significantly expanding its commercial portfolio in endocrinology and rare diseases. The deal centers on Soleno’s drug Vykat XR, approved in 2025 for extreme hunger in Prader-Willi syndrome patients. Despite the 51% premium offered, analysts at Stifel expressed surprise at Soleno's acceptance, given the strong growth potential predicted for Vykat XR, which had already generated $190.4 million in sales for 1,250 patients in under a year.
How Will Skyrizi and Rinvoq Shape AbbVie's Q1 Immunology Sales?
AbbVie is set to report its first-quarter 2026 results, with investor attention focused on its immunology segment, particularly the performance of Skyrizi and Rinvoq. These drugs are crucial for driving growth following the loss of exclusivity for Humira. While Skyrizi and Rinvoq sales are expected to show strong growth, Humira sales are projected to decline significantly, and AbbVie faces increasing competition in the immunology market from companies like Johnson & Johnson and Eli Lilly.
Breast to lung cancers: IDEAYA puts IDE574 into human testing
IDEAYA Biosciences announced the first patient enrolled in its Phase 1 trial for IDE574, a potential first-in-class dual inhibitor of KAT6 and KAT7. This oral therapy targets solid tumors including breast, prostate, colorectal, and lung cancer, aiming for monotherapy efficacy and durable anti-tumor responses. Preclinical data show high potency and selectivity, with further details to be presented at AACR 2026.
Merck & Co., Inc. $MRK Shares Purchased by Savvy Advisors Inc.
Savvy Advisors Inc. increased its stake in Merck & Co., Inc. by 50.9% in Q4, acquiring 8,627 additional shares, bringing their total to 25,567 shares valued at $2.69 million. This occurred despite significant insider selling totaling over $38 million in the past three months. Merck reported strong quarterly earnings, beating estimates, and announced a quarterly dividend of $0.85 per share along with positive news regarding new drug approvals and trial results.
Bristol-Myers Squibb Company stock: What you should know now
This report provides an in-depth analysis of Bristol-Myers Squibb Company stock, assessing its business, risks, and analyst views to help investors decide if it's a worthwhile addition to their portfolio. It covers the company's strong oncology and immunology lineup, financial performance, strategic market position, and potential risks like tariff proposals and patent expirations. The article also highlights analyst sentiment and key factors investors should monitor for future performance.
Amgen Inc. stock: Pipeline pivot eyes $37-38B sales amid biosimilar risks
Amgen Inc. is strategically pivoting its pipeline to achieve $37-38.4 billion in sales by 2026, driven by next-generation drugs like the obesity candidate MariTide. This move is crucial for counteracting biosimilar erosion on its legacy products and positions Amgen as a resilient biotech play with strong dividend potential for global investors. The company aims to balance mature cash cows with innovative treatments in key areas like obesity and oncology, while maintaining robust financial health and attractive margins.
Capricorn Fund Managers Ltd Invests $4.12 Million in Pfizer Inc. $PFE
Capricorn Fund Managers Ltd recently invested $4.12 million to acquire a new stake of 165,569 shares in Pfizer Inc. during the fourth quarter. This move comes as Pfizer reported strong Q4 results, surpassing analyst expectations with $0.66 EPS and $17.56 billion in revenue, despite a slight year-over-year revenue decrease. Institutional investors collectively own a significant portion of Pfizer, holding about 68.36% of the company's stock, while analysts currently maintain an average "Hold" rating with a target price of $28.19.
EA Bridgeway Blue Chip ETF (BBLU) Stock Price, Holdings, Dividend Yield
This article provides a detailed overview of the EA Bridgeway Blue Chip ETF (BBLU), including its current stock price, key statistics, holdings, and performance data. As of the latest filing on 2025-12-31, the ETF holds 37 stocks with a total value of $354.00 million, and its top holdings include Broadcom (AVGO), JPMorgan Chase (JPM), and NVIDIA (NVDA). The report also details the fund's historical performance, dividend information, and significant trades.
Antibodies Market To Witness Substantial Growth, 2026-2033 | Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc.
The Antibodies Market is projected to experience substantial growth,
Eli Lilly and Company (NYSE:LLY) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Eli Lilly and Company's stock rating from "strong-buy" to "buy" despite recent positive developments like the FDA approval of Foundayo and strong quarterly earnings. The article also notes other analyst actions, current stock performance data, and significant institutional investor activity. While Eli Lilly continues to expand its pipeline with acquisitions and new drug approvals, competitive pressures and broader market risks are highlighted.
Jim Cramer Discusses Newmont Corporation and the Importance of Owning Gold
Jim Cramer discussed Newmont Corporation (NEM) and emphasized the importance of owning gold, stating he prefers both physical gold and gold miners like Newmont. He expressed interest in hearing more from Newmont's CEO, Natascha Viljoen, to understand how the company compares to others he follows closely, such as Agnico. Newmont is a mining company that explores for and produces various metals, including gold.
How Investors May Respond To WEX (WEX) GLP‑1 HRA Launch And Impactive Proxy Challenge
WEX Inc. recently launched a specialized Health Reimbursement Arrangement (HRA) to help employers manage GLP-1 medication costs, leveraging its existing benefits and payments infrastructure. This move is expected to bolster WEX's healthcare benefits segment growth and diversify its revenue streams beyond traditional fuel payments. While the HRA and a concurrent proxy contest with Impactive Capital are relevant for sentiment and governance, they don't significantly alter the core investment drivers of WEX's integrated payments and benefits platform.
A Look At Bristol Myers Squibb (BMY) Valuation After US Tariff Threats Hit Pharma Stocks
Bristol-Myers Squibb (BMY) is facing reassessment from investors due to potential US tariffs on imported branded drugs. Despite recent stock cooling, the company is trading about 5% below the average analyst price target and shows an intrinsic discount of around 51%. The valuation narrative suggests a fair value of $65.00, marking it as undervalued, but this depends on effective cost-saving and managing tariff risks.
Jim Cramer Discusses Why Thomson Reuters Became an AI Casualty
Jim Cramer highlighted Thomson Reuters Corporation (NASDAQ: TRI) as an AI casualty, noting it was the eighth-worst performer in the Nasdaq 100 for the first quarter, with a nearly 32% decline. The company, which provides financial data and legal research via Westlaw, is facing fears of AI competition, as new AI systems can quickly perform tasks previously handled by their software. Cramer questioned whether investors would stick with Thomson Reuters given these emerging AI capabilities.
Jim Cramer Says “In Fairness, Zscaler Shouldn’t Have Been Hit All That Hard”
Jim Cramer discussed Zscaler (NASDAQ: ZS) and its performance, noting that despite a significant drop, the cybersecurity company shouldn't have been hit so hard. While he prefers CrowdStrike or Palo Alto Networks for cybersecurity investments, Cramer advised a caller against selling Zscaler immediately, suggesting lightening up positions after a bounce due to holding multiple similar stocks. The article concludes by recommending a different AI stock with high upside potential over Zscaler.
Jim Cramer on Lockheed Martin: “That’s the One I Would Tell You to Buy”
Jim Cramer recommends Lockheed Martin Corporation (NYSE: LMT) as a buying opportunity, citing CEO Jim Taiclet's leadership and the recent dip in aerospace and defense stocks. He believes the increasing defense budget further strengthens the stock's prospects. Despite his confidence in LMT, the article highlights the potential of certain AI stocks for higher and faster returns.
Replimune Sees Positive Momentum Amid Strategic Developments
Replimune Group Inc. (NASDAQ: REPL) has seen its stock rise by 10.78% due to strategic developments, partnerships, and a strong cash position, despite facing significant financial challenges like negative EBITDA and net income. Analysts are cautiously optimistic about its growth potential, highlighting R&D investments and a recent strategic acquisition, while noting the need for improved operational efficiency and breakthrough innovations. The company's financial health shows robust liquidity but also a moderate debt level, making future strategic financial planning crucial for its ascent in the biotech sector.
JB Capital LLC Boosts Holdings in Merck & Co., Inc. $MRK
JB Capital LLC increased its stake in Merck & Co., Inc. (NYSE:MRK) by 7.3% in the fourth quarter, bringing its total holdings to 137,269 shares valued at $14.45 million. Multiple other institutional investors also increased their positions in Merck, which reported strong Q4 earnings, positive pipeline developments including EU approval for KEYTRUDA and new trials for MK‑8748 and an oral PCSK9 inhibitor, and announced a quarterly dividend. Analysts maintain a "Moderate Buy" consensus rating for the company, despite some negative sentiment regarding potential tariffs and drug-pricing debates.
Elevance Health Outpaces Smaller Rival Selectis Health
This article compares Elevance Health (NYSE: ELV) and Selectis Health (OTCMKTS: GBCS), concluding that Elevance is a better long-term investment due to its larger size, stronger financials, and greater institutional support. It highlights the competitive advantage of scale and financial strength in the healthcare industry, noting Elevance's higher revenue, earnings, profitability, and lower stock volatility compared to Selectis Health.
AbbVie Inc. (ABBV) stock price, news, quote and history
This article provides a comprehensive overview of AbbVie Inc. (ABBV) stock, including its current price, historical data, financial performance, and analyst insights. It details the company's diverse portfolio of pharmaceutical products and therapeutic areas, along with a comparison to other major drug manufacturers. The stock's performance metrics, earnings trends, and key valuation measures are also presented.
Herbst Group LLC Invests in Eli Lilly and Company
Herbst Group LLC has acquired a new stake of 1,925 shares in Eli Lilly and Company, valued at approximately $2.07 million, indicating confidence in the pharmaceutical giant's growth potential. This investment was disclosed in a recent SEC filing, highlighting Eli Lilly's continued ability to attract significant institutional investment. Other firms have also adjusted their holdings, reinforcing positive investor sentiment toward the company.
Aberdeen Group plc Acquires 64,561 Shares of Inspire Medical Systems, Inc. $INSP
Aberdeen Group plc increased its stake in Inspire Medical Systems (NYSE:INSP) by 16.3% in Q4 2025, purchasing 64,561 shares to hold a total of 460,901 shares valued at approximately $42.51 million. Inspire Medical Systems exceeded Q4 earnings expectations with an EPS of $1.65 and revenue of $269.1 million, despite analyst sentiment cooling to a "Hold" rating with an average target price of $104.24. The company has a current market cap of $1.58 billion and its stock opened at $54.93 on Friday.
